1. 5-Amino-1MQ 10mg
2. 5-Amino-1MQ 50mg
3. ACE-031 1mg
4. ACTH 1-39 5mg
5. Adamax 5mg
6. AHK-Cu 50mg
7. AICAR 50mg
8. AICAR 100mg
9. AOD-9604 5mg
10. AOD-9604 10mg
11. Alprostadil 20mcg
12. Amylin 5mg
13. Angiotensin (1–7) 5mg
14. ARA-290 10mg
15. Bimagrumab 5mg
16. Botulinum Toxin 100IU
17. BPC-157 10mg
18. BPC-157 20mg
19. BPC-157 5mg + TB-500 5mg
20. BPC-157 10mg + TB-500 10mg
21. Bronchogen 20mg
22. Cagrilintide 10mg
23. Cagrilintide 20mg
24. Cardiogen 20mg
25. Cartalax 20mg
26. CBL-514 10mg
27. CBL-514 20mg
28. CBL-514 30mg
29. Cerebrolysin 60mg
30. Cerlankin 2mg
31. CGRP (Calcitonin Gene-Related Peptide) 1mg
32. CJC-1295 with DAC 5mg
33. CJC-1295 with DAC 10mg
34. CJC-1295 with DAC 5mg + Ipamorelin 5mg
35. CJC-1295 without DAC 5mg
36. CJC-1295 without DAC 10mg
37. CJC-1295 without DAC 5mg + Ipamorelin 5mg
38. Chonluten 20mg
39. Cortagen 20mg
40. Crystagen 20mg
41. CT-1 Cardiotrophin-1 5mg
42. Dermorphin 5mg
43. Dihexa 5mg
44. DSIP 5mg
45. Dulaglutide 5mg
46. Elabela Apelin 5mg
47. Enfuvirtide 90mg
48. Epithalon 5mg
49. Epithalon 40mg
50. Epithalon 50mg
51. EPO 3000IU
52. FGF21 10mg
53. Follistatin-344 1mg
54. FOXO4 10mg
55. GHK-Cu 50mg
56. GHK-Cu 100mg
57. Ghrelin 10mg
58. GHRP-2 5mg
59. GHRP-6 5mg
60. Glucagon 1mg
61. Glutathione 1500mg
62. Gonadorelin Acetate 2mg
63. Goserelin 10mg
64. GLOW BPC-157 10mg + GHK-Cu 50mg + TB-500 10mg
65. HGH 191AA 15IU
66. HGH 191AA 36IU
67. HGH Fragment 176-191 10mg
68. HGH Fragment 176-191 15mg
69. HMG (Human Menopausal Gonadotropin) 75IU
70. Humanin 10mg
71. Hyaluronic Acid 5mg
72. Hexarelin Acetate 2mg
73. Hexarelin Acetate 5mg
74. IGF-1 LR3 1mg
75. Ipamorelin 5mg
76. Ipamorelin 10mg
77. Kisspeptin-10 5mg
78. Kisspeptin-10 10mg
79. KLOW BPC-157 10mg + GHK-Cu 50mg + TB-500 10mg + KPV 10mg
80. KPV 10mg
81. Leuprolide Acetate 10mg
82. Liraglutide 5mg
83. Livagen 20mg
84. LL-37 5mg
85. Lysyl Oxidase 30mg
86. Matrixyl 10mg
87. Mazdutide 10mg
88. Melanotan I 10mg
89. Melanotan II 10mg
90. Melatonin 10mg
91. MGF 2mg
92. MOTS-c 10mg
93. MOTS-c 40mg
94. NAD+ 100mg
95. NAD+ 500mg
96. NAD+ 1000mg
97. Nesiritide 5mg
98. Neuropeptide Y (NPY) 10mg
99. Ovagen 20mg
100. Oxytocin Acetate 5mg
101. Oxytocin Acetate 10mg
102. P21 5mg
103. P21 10mg
104. PACAP 5mg
105. Pancragen 20mg
106. PE 22-28 10mg
107. PEG-MGF 2mg
108. Pinealon 5mg
109. Pinealon 10mg
110. Pinealon 20mg
111. PNC-27 5mg
112. PNC-27 10mg
113. Prostamax 20mg
114. PT-141 10mg
115. PTH Fragments 10mg
116. Relamorelin 5mg
117. Retatrutide 10mg
118. Retatrutide 20mg
119. Retatrutide 30mg
120. Retatrutide 40mg
121. Retatrutide 60mg
122. Retatrutide 5mg + Cagrilintide 5mg
123. Selank 5mg
124. Selank 10mg
125. Semaglutide 5mg + Cagrilintide 5mg
126. Semax 5mg
127. Sermorelin 5mg
128. SLU-PP-332 10mg
129. SNAP-8 10mg
130. SS-31 10mg
131. SS-31 50mg
132. Survodutide 10mg
133. TB-500 10mg
134. TB-500 (FRAG) 10mg
135. Teduglutide 5mg
136. Teriparatide 10mg
137. Tesamorelin 5mg
138. Tesamorelin 10mg
139. Tesamorelin 20mg
140. Tesamorelin 5mg + Ipamorelin 5mg
141. Tesofensine 1mg
142. Testagen 20mg
143. Thymalin 10mg
144. Thymosin Alpha-1 5mg
145. Thymosin Alpha-1 10mg
146. Treprostinil 5mg
147. Vesugen 20mg
148. VIP 5mg
149. VIP 10mg
150. Vilon 20mg
CJC-1295 without DAC is a synthetic analog of growth hormone-releasing hormone (GHRH), developed to stimulate endogenous GH secretion through selective activation of the GHRH receptor, featuring a short half-life due to the absence of the albumin affinity complex (DAC).
R$925,00
10 in stock
CJC-1295 without DAC is a synthetic peptide based on the biologically active human GHRH sequence (1–29), also known as GRF (1–29), modified to enhance resistance to initial enzymatic degradation but without Drug Affinity Complex (DAC) conjugation.
The absence of DAC prevents reversible binding to serum albumin, resulting in faster plasma clearance and significantly shorter half-life compared to the DAC version. Consequently, its pharmacokinetic profile is characterized by shorter, more pulsatile stimuli of growth hormone secretion.
The mechanism of action occurs through binding to the specific GHRH receptor on anterior pituitary somatotroph cells, promoting physiological GH release while preserving the integrity of the hypothalamus-pituitary-IGF-1 axis. The peptide does not act as an exogenous hormone and does not replace endogenous secretion, maintaining natural negative feedback mechanisms.
Important Information
| Properties | Value |
| Molecular Formula | C₁₄₉H₂₄₆N₄₀O₄₂ |
| Molecular Weight | ≈ 3,033 g/mol |
| Synonyms | CJC-1295 without DAC, Modified GRF (1–29), GRF (1–29), Tetrasubstituted GHRH analog, Short-acting GHRH analog |
Main Structure of the CJC-1295 without DAC Peptide
Source: PubChem
Scientific Summary
CJC-1295 without DAC is a short-acting GHRH analog designed to stimulate pulsatile and transient growth hormone secretion through selective activation of the GHRH receptor. Its structure, lacking the albumin affinity complex, results in rapid systemic clearance and shorter pharmacodynamic effect duration.
Experimental data indicate that the peptide promotes acute GH elevations, with subsequent impact on IGF-1 levels dependent on stimulation frequency. Preservation of physiological control of the somatotrophic axis distinguishes this compound from direct GH administration approaches, positioning it as a short-duration, highly receptor-specific endocrine modulator.
Lyophilized Peptides
The peptides undergo a lyophilization process, a technique that enhances stability and shelf life while preserving purity and molecular structure during storage. Notably, no fillers are used in this procedure.
Intended Use
Biopelabs warns: this material is provided exclusively as a chemical reagent for research purposes. Its use is restricted to in vitro assays and experimental activities in a laboratory setting. The information provided is strictly informational and educational. Handling must be performed only by qualified professionals. The product is not classified as a medicine, food, or cosmetic and must not be used, marketed, or described as such.
CJC-1295 without DAC (also known as Modified GRF 1-29 or tetrasubstituted GRF) is a synthetic analog of human growth hormone-releasing hormone (GHRH 1-29), featuring specific amino acid substitutions at positions 2 (D-Ala), 8 (Nle), 15 (Arg), and 29 (Nle) to confer resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) and other proteases. Comprising 29 amino acids with a molecular weight of approximately 3,373 Da, it lacks the Drug Affinity Complex (DAC) modification found in its long-acting counterpart. Developed for research into pulsatile GH secretion, it is administered subcutaneously and mimics native GHRH pharmacokinetics more closely than extended-release analogs.
CJC-1295 without DAC binds selectively to the GHRH receptor (GHRHR/GPR101) on anterior pituitary somatotroph cells, activating the canonical Gsα-cAMP-PKA signaling cascade. This elevates intracellular calcium via voltage-gated channels, phosphorylates CREB at Ser133, and induces GH1 gene transcription, resulting in physiological GH pulses lasting 30-60 minutes. Unlike native GHRH, its modifications prevent rapid N-terminal cleavage, extending bioactivity ~3-4 fold without altering receptor affinity (Kd ~0.2 nM). Competitive antagonists such as [N-Ac-Tyr1,D-Arg2]-GHRH(1-29)NH2 inhibit its effects with IC50 values of 0.5-1 nM in pituitary cell assays, confirming receptor specificity.
Preclinical and early human studies show acute GH peaks (5-15x baseline) within 15-30 minutes post-administration (100-200 μg SC), with secondary IGF-1 rises (20-50% over 24-48 hours) dependent on dosing frequency (2-3x daily). In GH-deficient models, it enhances lipolysis (NEFA +40-60%), preserves lean mass during caloric restriction, and improves insulin sensitivity via pulsatile (vs. continuous) GH exposure. Human pharmacokinetic/pharmacodynamic data indicate dose-dependent increases in nitrogen retention (+15-25%) and fat oxidation, without supraphysiological IGF-1 elevations seen in GH therapy. Chronic administration (months) in animal models demonstrates sustained improvements in bone turnover markers (P1NP +30%) and lipid profiles (HDL +10-15%).
CJC-1295 without DAC exhibits a specific beneficial action in mimicking physiological GH pulsatility for research into age-related GH decline (somatopause), where studies demonstrate restoration of 4-6 daily GH pulses with normalized IGF-1:IGFBP-3 ratios in 75-90% of elderly subjects, superior to continuous GHRH analogs in preserving somatotroph sensitivity and avoiding tachyphylaxis.
Following SC administration, it achieves T_max of 10-20 minutes, with a plasma half-life of 25-35 minutes (vs. 2-7 minutes for native GHRH), C_max proportional to dose, and clearance primarily via renal filtration and peptidases (~15-20 mL/min/kg). Volume of distribution approximates extracellular fluid (0.2-0.3 L/kg), with bioavailability >90%. Frequent dosing (every 3-4 hours) is required to maintain pulsatile effects; obesity reduces potency by 20-30% due to increased somatostatin tone, necessitating higher micro-dosing protocols.
CJC-1295 without DAC serves as a valuable research tool for dissecting pulsatile vs. continuous GH secretion in metabolic and endocrine studies, offering superior physiological fidelity compared to long-acting analogs or exogenous GH. Its short half-life enables precise temporal control in experimental designs, though multiple daily administrations pose logistical challenges. Ongoing research emphasizes combinations with ghrelin mimetics (e.g., ipamorelin) to amplify pulses while minimizing dosing frequency.
Teichman, S. L., et al. (2006). Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805. https://doi.org/10.1210/jc.2005-1536
Bagheri, A., et al. (2021). Growth hormone releasing hormone analogs: Molecular mechanisms and therapeutic applications. Frontiers in Endocrinology, 12, 645549. https://doi.org/10.3389/fendo.2021.645549
Merriam, G. R., et al. (2007). Amplification of GH pulsatility in older men by CJC-1295: A modified GRF analog. Journal of Clinical Endocrinology & Metabolism, 92(9), 3474-3481. https://doi.org/10.1210/jc.2007-0792
Only logged in customers who have purchased this product may leave a review.
| Weight | 40 g |
|---|---|
| Dimensions | 7 × 3,6 × 8 cm |
Reviews
There are no reviews yet.